Champions Oncology, Inc. (CSBR)
CSBR Stock Price Chart
Explore Champions Oncology, Inc. interactive price chart. Choose custom timeframes to analyze CSBR price movements and trends.
CSBR Company Profile
Discover essential business fundamentals and corporate details for Champions Oncology, Inc. (CSBR) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
2 Feb 2007
Employees
210.00
CEO
Robert Brainin
Description
Champions Oncology, Inc. is dedicated to developing and commercializing cutting-edge technological products and services designed to personalize cancer treatment and streamline the development of oncology drugs across the United States. At the heart of its offerings is the Tumorgraft Technology Platform, an innovative approach that facilitates individualized cancer care by implanting human tumors into immune-deficient mice. Utilizing this proprietary platform, the company not only delivers personalized cancer solutions directly but also provides Translational Oncology Solutions, supporting pharmaceutical and biotechnology companies through their drug development lifecycle. Additionally, Champions Oncology offers Lumin Bioinformatics, a comprehensive software platform and data tool filled with insights from research services and clinical studies, accessible through annual subscriptions. The company distributes its offerings through various channels, including online platforms, word-of-mouth referrals, and a dedicated sales team, reaching both patients and healthcare professionals. Established in 1985, Champions Oncology, Inc. is based in Hackensack, New Jersey, and was formerly known as Champions Biotechnology, Inc. until its name change in April 2011.
CSBR Financial Timeline
Browse a chronological timeline of Champions Oncology, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 16 Sept 2026
EPS estimate is -$0.01, while revenue estimate is $15.05m.
Earnings released on 17 Jul 2026
Earnings released on 12 Mar 2026
EPS came in at -$0.02 falling short of the estimated $0.09 by -122.22%, while revenue for the quarter reached $16.56m , missing expectations by -0.33%.
Earnings released on 15 Dec 2025
EPS came in at $0.02 falling short of the estimated $0.08 by -75.00%, while revenue for the quarter reached $15.04m , missing expectations by -8.47%.
Earnings released on 15 Sept 2025
EPS came in at -$0.03 falling short of the estimated $0.01 by -400.00%, while revenue for the quarter reached $14.00m , missing expectations by -0.33%.
Earnings released on 23 Jul 2025
EPS came in at -$0.13 falling short of the estimated $0.06 by -316.67%, while revenue for the quarter reached $12.36m , missing expectations by -15.76%.
Earnings released on 11 Mar 2025
EPS came in at $0.31 surpassing the estimated -$0.01 by +3.20k%, while revenue for the quarter reached $17.04m , beating expectations by +41.84%.
Earnings released on 11 Dec 2024
EPS came in at $0.05 surpassing the estimated $0.01 by +400.00%, while revenue for the quarter reached $13.49m , beating expectations by +3.33%.
Earnings released on 11 Sept 2024
EPS came in at $0.11 surpassing the estimated $0.02 by +466.72%, while revenue for the quarter reached $14.06m , beating expectations by +6.28%.
Earnings released on 18 Jul 2024
EPS came in at -$0.01 surpassing the estimated -$0.16 by +93.75%, while revenue for the quarter reached $14.00m , beating expectations by +10.33%.
Earnings released on 12 Mar 2024
EPS came in at -$0.19 falling short of the estimated -$0.06 by -216.67%, while revenue for the quarter reached $12.02m , missing expectations by -5.29%.
Earnings released on 12 Dec 2023
EPS came in at -$0.15 surpassing the estimated -$0.17 by +11.76%, while revenue for the quarter reached $11.57m , missing expectations by -9.87%.
Earnings released on 13 Sept 2023
EPS came in at -$0.19 falling short of the estimated -$0.10 by -90.00%, while revenue for the quarter reached $12.56m , missing expectations by -3.82%.
Earnings released on 24 Jul 2023
EPS came in at -$0.19 falling short of the estimated -$0.12 by -58.33%, while revenue for the quarter reached $13.07m , beating expectations by +1.64%.
Earnings released on 15 Mar 2023
EPS came in at -$0.18 falling short of the estimated -$0.06 by -200.00%, while revenue for the quarter reached $12.77m , missing expectations by -0.68%.
Earnings released on 13 Dec 2022
EPS came in at -$0.00 falling short of the estimated -$0.00 by -100.00%, while revenue for the quarter reached $14.28m , beating expectations by +3.57%.
Earnings released on 8 Sept 2022
EPS came in at -$0.02 falling short of the estimated -$0.01 by -300.00%, while revenue for the quarter reached $13.75m , beating expectations by +2.12%.
Earnings released on 21 Jul 2022
EPS came in at -$0.03 falling short of the estimated -$0.01 by -220.17%, while revenue for the quarter reached $12.88m , beating expectations by +0.86%.
Earnings released on 15 Mar 2022
EPS came in at $0.05 surpassing the estimated $0.03 by +100.00%, while revenue for the quarter reached $13.19m , beating expectations by +1.24%.
Earnings released on 13 Dec 2021
EPS came in at $0.02 surpassing the estimated $0.01 by +300.00%, while revenue for the quarter reached $11.79m , missing expectations by -5.49%.
Earnings released on 13 Sept 2021
EPS came in at -$0.01 falling short of the estimated -$0.00 by -200.30%, while revenue for the quarter reached $11.25m , missing expectations by -62.96%.
Earnings released on 22 Jul 2021
EPS came in at -$0.04 falling short of the estimated $0.01 by -500.00%, while revenue for the quarter reached $10.57m , missing expectations by -3.69%.
CSBR Stock Performance
Access detailed CSBR performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
